XML 53 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Segment and Geographic Information
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Segment and Geographic Information

15.

Segment and Geographic Information

The Company has determined that the chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews financial information presented for the Company’s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.

Geographic Revenues

Geographic revenues, which are based on the bill-to region, are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

Europe

 

$

67,161

 

 

$

132,400

 

 

$

112,916

 

Japan

 

 

36,660

 

 

 

122,475

 

 

 

100,002

 

China

 

 

72,498

 

 

 

1,700

 

 

 

—

 

All other

 

 

—

 

 

 

2

 

 

 

40

 

Total revenue

 

$

176,319

 

 

$

256,577

 

 

$

212,958

 

Geographic Assets

Inventory by geographic location are as follows (in thousands):

 

 

December 31,

 

 

 

2020

 

 

2019

 

United States

 

$

4,715

 

 

$

—

 

China

 

 

11,815

 

 

 

6,887

 

Total inventory

 

$

16,530

 

 

$

6,887

 

Property and equipment, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

United States

 

$

20,673

 

 

$

27,325

 

China

 

 

12,974

 

 

 

15,418

 

Total property and equipment

 

$

33,647

 

 

$

42,743

 

 

Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

United States

 

$

29,551

 

 

$

39,237

 

China

 

 

55

 

 

 

365

 

Total finance lease right-of-use assets

 

$

29,606

 

 

$

39,602

 

 

 

 

 

 

 

 

 

 

United States

 

$

47

 

 

$

75

 

China

 

 

1,996

 

 

 

1,856

 

Total operating lease right-of-use assets

 

$

2,043

 

 

$

1,931

 

 

Customer Concentration

The Company’s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company’s total revenue and accounts receivable:

 

 

 

Percentage of Revenue

 

 

Percentage of Accounts Receivable

 

 

 

Years Ended December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

2018

 

 

2020

 

 

2019

 

Astellas—Related party

 

 

21

%

 

 

48

%

 

 

47

%

 

 

10

%

 

 

17

%

AstraZeneca

 

 

37

%

 

 

52

%

 

 

53

%

 

 

26

%

 

 

81

%

 

The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. For the year ended December 31, 2020, the aggregate revenue from distributors represented 42% of the consolidated revenue, with no individual distributor representing over 10% of the total revenue. As of December 31, 2020, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor. The aggregate revenue from distributors for the year ended December 31, 2019 and the aggregate accounts receivable from distributors as of December 31, 2019 were immaterial.